| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Circulation, Vol 77, 142-150, Copyright © 1988 by American Heart Association
DJ Fitzgerald, F Catella, L Roy and GA FitzGerald
We assessed thromboxane biosynthesis as an index of platelet activation in
6 patients with acute myocardial infarction receiving intravenous
streptokinase. Urinary 2,3-dinor-thromboxane B2 and plasma 11-dehydro-
thromboxane B2, major enzymatic metabolites of thromboxane A2, were
markedly increased after intravenous streptokinase (11,063 +/- 2758 pg/mg
creatinine and 33 +/- 10 pg/ml, respectively) compared with levels in
patients not receiving thrombolytic therapy (502 +/- 89 pg/mg creatinine
and 3 +/- 0.7 pg/ml). Prostacyclin biosynthesis also increased markedly
after streptokinase coincident with the increase in thromboxane A2
formation. Administration of aspirin between the time of onset of coronary
thrombosis and reperfusion both in man and in a canine preparation
demonstrated that this reflected thromboxane biosynthesis de novo and not
metabolism of preformed inactive thromboxane B2 washed out from the
coronary circulation. Since the platelet is the major source of thromboxane
A2, these findings suggest that there is marked platelet activation after
coronary thrombolysis with streptokinase. Studies in vitro demonstrated
that streptokinase enhanced platelet activation in a dose-dependent manner,
resulting in the secondary release of thromboxane A2. The increase in
platelet activation and thromboxane A2 biosynthesis may limit the
therapeutic effect of intravenous streptokinase in acute myocardial
infarction.
ARTICLES
Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction
Divisions of Clinical Pharmacology, Vanderbilt University, Nashville, TN 37232.
This article has been cited by other articles:
 |
|
 |
|
  D. Dudek, T. Rakowski, A. Dziewierz, and P. Kleczynski PCI after lytic therapy: when and how? Eur. Heart J. Suppl., December 1, 2008; 10(suppl_J): J15 - J20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Woollard, P. C Elwood, and G. Morgan Life saving early and immediate aspirin: too little too late Postgrad. Med. J., July 1, 2008; 84(993): 337 - 338. [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. FitzGerald Summary Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s51 - s52. [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Kloner, M. B. Forman, R. J. Gibbons, A. M. Ross, R. W. Alexander, and G. W. Stone Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial Eur. Heart J., October 2, 2006; 27(20): 2400 - 2405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Collet and G. Montalescot Premature withdrawal and alternative therapies to dual oral antiplatelet therapy Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G46 - G52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Gibson, L. K. Jennings, S. A. Murphy, D. P. Lorenz, R. P. Giugliano, R. A. Harrington, S. Cholera, R. Krishnan, R. M. Califf, E. Braunwald, et al. Association Between Platelet Receptor Occupancy After Eptifibatide (Integrilin) Therapy and Patency, Myocardial Perfusion, and ST-Segment Resolution Among Patients With ST-Segment-Elevation Myocardial Infarction: An INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) Substudy Circulation, August 10, 2004; 110(6): 679 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M W H Behan and R F Storey Antiplatelet therapy in cardiovascular disease Postgrad. Med. J., March 1, 2004; 80(941): 155 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Wong, R. P. Giugliano, and E. M. Antman Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention JAMA, January 15, 2003; 289(3): 331 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. F. Baker Jr Thrombolytic Therapy Clinical and Applied Thrombosis/Hemostasis, October 1, 2002; 8(4): 291 - 314. [PDF]
|
|
|
|
|
|
S. Kamath, A.D. Blann, and G.Y.H. Lip Platelets and atrial fibrillation Eur. Heart J., December 2, 2001; 22(24): 2233 - 2242. [PDF]
|
|
|
|
|
|
J. Llevadot, R. P. Giugliano, and E. M. Antman Bolus Fibrinolytic Therapy in Acute Myocardial Infarction JAMA, July 25, 2001; 286(4): 442 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Herrmann, D. J. Moliterno, E. M. Ohman, A. L. Stebbins, C. Bode, A. Betriu, F. Forycki, J. S. Miklin, W. B. Bachinsky, A. M. Lincoff, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4 Pilot) trial J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1489 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cox, R. Smith, M. Quinn, P. Theroux, P. Crean, and D. J. Fitzgerald Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1514 - 1519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Belton, D. Byrne, D. Kearney, A. Leahy, and D. J. Fitzgerald Cyclooxygenase-1 and -2-Dependent Prostacyclin Formation in Patients With Atherosclerosis Circulation, August 22, 2000; 102(8): 840 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Coulter, C. P. Cannon, K. A. Ault, E. M. Antman, F. Van de Werf, A. A. J. Adgey, C. M. Gibson, R. P. Giugliano, M. A. Mascelli, J. Scherer, et al. High Levels of Platelet Inhibition With Abciximab Despite Heightened Platelet Activation and Aggregation During Thrombolysis for Acute Myocardial Infarction : Results From TIMI (Thrombolysis In Myocardial Infarction) 14 Circulation, June 13, 2000; 101(23): 2690 - 2695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. McRedmond, P. Harriott, B. Walker, and D. J. Fitzgerald Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1 Blood, February 15, 2000; 95(4): 1301 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Neufeld, U. Nowak-Gottl, and R. Junker Citrate-Theophylline-Adenine-Dipyridamol Buffer Is Preferable to Citrate Buffer as an Anticoagulant for Flow Cytometric Measurement of Platelet Activation Clin. Chem., November 1, 1999; 45(11): 2030 - 2033. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Lawson, J. Rokach, and G. A. FitzGerald Isoprostanes: Formation, Analysis and Use As Indices of Lipid Peroxidation in Vivo J. Biol. Chem., August 27, 1999; 274(35): 24441 - 24444. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman, R. P. Giugliano, C. M. Gibson, C. H. McCabe, P. Coussement, N. S. Kleiman, A. Vahanian, A. A. J. Adgey, I. Menown, H.-J. Rupprecht, et al. Abciximab Facilitates the Rate and Extent of Thrombolysis : Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 Trial Circulation, June 1, 1999; 99(21): 2720 - 2732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Reilly, D. Pratico, N. Delanty, G. DiMinno, E. Tremoli, D. Rader, S. Kapoor, J. Rokach, J. Lawson, and G. A. FitzGerald Increased Formation of Distinct F2 Isoprostanes in Hypercholesterolemia Circulation, December 22, 1998; 98(25): 2822 - 2828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Murphy, D. Pratico, and D. J. Fitzgerald Functional Relevance of the Expression of Ligand-Induced Binding Sites in the Response to Platelet GP IIb/IIIa Antagonists In Vivo. J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 945 - 951. [Abstract] [Full Text]
|
|
|
|
 |
|
 A H Gershlick and R S More Recent advances: Treatment of myocardial infarction BMJ, January 24, 1998; 316(7127): 280 - 284. [Full Text]
|
|
|
|
|
|
M. P. Reilly, N. Delanty, L. Roy, J. Rokach, P. O. Callaghan, P. Crean, J. A. Lawson, and G. A. FitzGerald Increased Formation of the Isoprostanes IPF2{alpha}-I and 8-Epi-Prostaglandin F2{alpha} in Acute Coronary Angioplasty : Evidence for Oxidant Stress During Coronary Reperfusion in Humans Circulation, November 18, 1997; 96(10): 3314 - 3320. [Abstract] [Full Text]
|
|
|
|
|
|
D. J. Schneider, P. B. Tracy, K. G. Mann, and B. E. Sobel Differential Effects of Anticoagulants on the Activation of Platelets Ex Vivo Circulation, November 4, 1997; 96(9): 2877 - 2883. [Abstract] [Full Text]
|
|
|
|
|
|
A. Byrne, N. Moran, M. Maher, N. Walsh, P. Crean, and D. J. Fitzgerald Continued Thromboxane A2 Formation Despite Administration of a Platelet Glycoprotein IIb/IIIa Antagonist in Patients Undergoing Coronary Angioplasty Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 3224 - 3229. [Abstract] [Full Text]
|
|
|
|
|
|
H. D. White, P. E. Aylward, M. J. Frey, A. A. J. Adgey, R. Nair, W. S. Hillis, Y. Shalev, M. A. Brown, J. K. French, R. Collins, et al. Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO) Circulation, October 7, 1997; 96(7): 2155 - 2161. [Abstract] [Full Text]
|
|
|
|
|
|
N. Delanty, M.P. Reilly, D. Pratico, J.A. Lawson, J.F. McCarthy, A.E. Wood, S.T. Ohnishi, D.J. Fitzgerald, and G.A. FitzGerald 8-Epi PGF2{alpha} Generation During Coronary Reperfusion: A Potential Quantitative Marker of Oxidant Stress In Vivo Circulation, June 3, 1997; 95(11): 2492 - 2499. [Abstract] [Full Text]
|
|
|
|
|
|
D. Pratico, N. P. Murphy, and D. J. Fitzgerald J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1178 - 1185. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Collins, R. Peto, C. Baigent, and P. Sleight Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction N. Engl. J. Med., March 20, 1997; 336(12): 847 - 860. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman Hirudin in Acute Myocardial Infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial Circulation, September 1, 1996; 94(5): 911 - 921. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. J. Eisenberg and E. J. Topol Prehospital Administration of Aspirin in Patients With Unstable Angina and Acute Myocardial Infarction Arch Intern Med, July 22, 1996; 156(14): 1506 - 1510. [Abstract] [PDF]
|
|
|
|
|
|
S. Waxman, M. A. Sassower, M. A. Mittleman, S. Zarich, A. Miyamoto, K. S. Manzo, J. E. Muller, G. S. Abela, and R. W. Nesto Angioscopic Predictors of Early Adverse Outcome After Coronary Angioplasty in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction Circulation, June 15, 1996; 93(12): 2106 - 2113. [Abstract] [Full Text]
|
|
|
|
|
|
E.J. Langford, R.J. Wainwright, and J.F. Martin Platelet Activation in Acute Myocardial Infarction and Unstable Angina Is Inhibited by Nitric Oxide Donors Arterioscler Thromb Vasc Biol, January 1, 1996; 16(1): 51 - 55. [Abstract] [Full Text]
|
|
|
|
|
|
D. Pratico, J. A. Lawson, and G. A. FitzGerald Cylooxygenase-dependent Formation of the Isoprostane, 8-Epi Prostaglandin F[IMAGE] J. Biol. Chem., April 28, 1995; 270(17): 9800 - 9808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Hansen Role of Neutrophils in Myocardial Ischemia and Reperfusion Circulation, March 15, 1995; 91(6): 1872 - 1885. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Goto, Y. Kawai, S. Abe, E. Takahashi, S. Handa, S. Ogawa, K. Watanabe, S. Hori, and Y. Ikeda Serial Changes in Coagulant Activities After Thrombolytic Therapy for Acute Myocardial Infarction Angiology, April 1, 1994; 45(4): 273 - 281. [Abstract] [PDF]
|
|
|
|
 |
|
 R. J. Shebuski Interruption of Thrombosis and Hemostasis by Anti-Platelet Agents Toxicol Pathol, January 1, 1993; 21(2): 180 - 189. [Abstract] [PDF]
|
|
|
|
 |
|
 J. J. Popma and E. J. Topol Adjuncts to Thrombolysis for Myocardial Reperfusion Ann Intern Med, July 1, 1991; 115(1): 34 - 44. [Abstract] [PDF]
|
|
|
|
|
|
D. C. Sane, R. M. Califf, E. J. Topol, D. C. Stump, D. B. Mark, and C. S. Greenberg Bleeding during Thrombolytic Therapy for Acute Myocardial Infarction: Mechanisms and Management Ann Intern Med, December 15, 1989; 111(12): 1010 - 1022. [Abstract] [PDF]
|
|
|
|
|
|
E. J. Topol Coronary Angioplasty for Acute Myocardial Infarction Ann Intern Med, December 15, 1988; 109(12): 970 - 980. [Abstract] [PDF]
|
|